Hypothesis

Senescent glomerular endothelial cells (GEnCs) release extracellular vesicles (EVs) enriched in miR-21 and PAI-1 that are taken up by adjacent tubular epithelial cells (TECs). Within TECs, EV‑delivered miR-21 suppresses PTEN, leading to Akt activation and subsequent NF‑κB signaling, while EV‑associated PAI-1 potentiates TGF‑β/Smad3 activity. The combined NF‑κB and Smad3 signaling synergistically induces p16INK4a transcription, triggering the tubular senescence cascade (ROS accumulation, SASP release, and profibrotic differentiation). This vesicle‑mediated paracrine mechanism explains the observed glomerular‑to‑tubular senescence transmission and positions EV biogenesis as a druggable checkpoint.

Testable Predictions

1. EV Isolation and Characterization – EVs harvested from cultured p21‑positive senescent GEnCs (or from kidneys of aged mice) will show elevated miR-21 and PAI-1 content compared with EVs from non‑senescent GEnCs.
2. Functional Transfer – Exposure of primary mouse TECs or human kidney tubuloids to senescent GEnC‑EVs will increase p16INK4a mRNA and protein, elevate ROS (e.g., MitoSOX signal), and upregulate SASP factors (IL-6, MCP-1) in a manner blocked by GW4869 (neutral sphingomyelinase inhibitor) or Rab27a knock‑down in GEnCs.
3. Mediator Dependency – AntagomiR‑21 neutralization or PAI‑1 blocking antibodies added to the EV‑TEC co‑culture will attenuate NF‑κB p65 phosphorylation, Smad3 nuclear translocation, and subsequent p16INK4a induction.
4. In Vivo Relevance – Endothelial‑specific deletion of Rab27a (using Tie2‑Cre;Rab27a^fl/fl mice) will reduce EV shedding, lower tubular p16INK4a accumulation, and protect against age‑related glomerulosclerosis and interstitial fibrosis, despite persistent glomerular p21+ senescence.
5. Therapeutic Implication – Pharmacological inhibition of EV release (e.g., with manumycin A) or miR‑21 antagomiR administered after onset of glomerular senescence will preserve GFR and reduce tubular injury markers more effectively than senolytics alone in unilateral ureteral obstruction (UUO) or aged mouse models.

Experimental Approach

• In Vitro: Isolate EVs from IFN‑γ/TNF‑α‑treated mouse glomerular endothelial cultures (p21+ confirmed by flow cytometry). Quantify miR-21 via qRT‑PCR and PAI‑1 by ELISA. Treat TECs with EVs ± GW4869, anti‑PAI‑1, or antagomiR‑21. Measure p16INK4a (Western blot, immunofluorescence), ROS (DCFDA), NF‑κB p65 phosphorylation, and Smad3 nuclear translocation. Include senescence‑associated β‑galactosidase staining as functional readout.
• Ex Vivo: Utilize precision‑cut kidney slices from young and old mice; apply labeled senescent GEnC‑EVs and track uptake into tubular compartments via confocal microscopy.
• In Vivo: Generate Tie2‑Cre;Rab27a^fl/fl mice and littermate controls. Subject cohorts to aging (18‑24 months) or induced glomerular injury (ADR model). Assess glomerular p21+ endothelial cells (immunostaining), tubular p16INK4a+ cells, EV numbers in kidney interstitial fluid (NTA), collagen deposition (Sirius Red), and functional parameters (serum creatinine, FITC‑inulin clearance).
• Intervention Studies: Treat aged wild‑type mice with manumycin A (EV release inhibitor) or miR‑21 antagomiR‑liposome complexes for 8 weeks; compare to navitoclax (senolytic) and placebo groups.

Falsifiability

If senescent GEnC‑EVs do not convey elevated miR-21/PAI-1, or if EV blockade fails to reduce tubular p16INK4a induction and downstream fibrotic outcomes, the hypothesis would be refuted. Conversely, a positive result would establish a novel mechanistic link between glomerular senescence and tubular pathology, prioritizing EV biogenesis or miR‑21 as therapeutic targets to interrupt the senescence cascade and preserve renal function.

Potential Impact

Demonstrating EV‑mediated senescence transmission would reconcile the observed temporal sequence (glomerular p21+ → podocyte loss → tubular injury) with a concrete molecular vector. It would also expand the senotherapeutic toolkit beyond cell clearance to include interception of pathogenic signaling vesicles, offering a stage‑specific strategy that could be applied early in aging‑related nephropathy before extensive tubular attrition occurs.